TCGA-CR-7371-01A-11R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.021461187
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.380
- KRAS_SIGNALING_UP+0.300
- ANDROGEN_RESPONSE+0.270
- ESTROGEN_RESPONSE_EARLY+0.270
- CHOLESTEROL_HOMEOSTASIS+0.210
- APICAL_SURFACE+0.200
- IL2_STAT5_SIGNALING+0.180
- ESTROGEN_RESPONSE_LATE+0.150
- INFLAMMATORY_RESPONSE+0.140
- UV_RESPONSE_DN+0.140
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.470
- OXIDATIVE_PHOSPHORYLATION-0.360
- DNA_REPAIR-0.330
- P53_PATHWAY-0.300
- INTERFERON_GAMMA_RESPONSE-0.290
- TNFA_SIGNALING_VIA_NFKB-0.270
- HYPOXIA-0.240
- MYC_TARGETS_V2-0.240
- MYC_TARGETS_V1-0.210
- MYOGENESIS-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_PSW27ZTE | EPN | EPN Tumor | 0.750 |
| 2 | TCGA-CR-5249-01A-01R-1514-07 | — | — | 0.685 |
| 3 | TCGA-CR-7364-01A-11R-2016-07 | — | — | 0.681 |
| 4 | TCGA-F7-7848-01A-11R-2132-07 | — | — | 0.662 |
| 5 | SRR934822 | — | — | 0.659 |
| 6 | MNG34 | — | — | 0.638 |
| 7 | TCGA-CN-6010-01A-11R-1686-07 | — | — | 0.603 |
| 8 | TCGA-OR-A5J2-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.588 |
| 9 | TCGA-CV-7101-01A-11R-2016-07 | — | — | 0.585 |
| 10 | MNG622 | — | — | 0.582 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.270 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.270 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.140 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.140 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.130 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.120 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.090 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| COMPLEMENT | 0.070 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.060 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.060 | Inavolisib | — uncovered |